SINGAPORE, June 6, 2018 /PRNewswire/ — Mundipharma has announced a licensing agreement with Korean biomedical firm, Genewel Co.Ltd, to market and distribute its GUARDIX-SG™ Surgical Adhesion Barrier portfolio across Southeast Asia.
GUARDIX-SG™ is used in surgery as a biodegradable mechanical barrier, reducing abnormal internal scarring post surgery by separating the internal tissues and organs while they heal.
First developed in Korea in 2010, it is a sterile, transparent, colorless adhesion barrier, formulated as a thermosensitive gel that remains as a solution at room temp but turns to viscous gel on contact with body temperature.
GUARDIX-SG™ is indicated as an adjunct in spine, thyroid and abdominal cavity surgeries to reduce the incidence, extent and severity of post-operative adhesions at the surgical site.
“As a scientifically-proven, safe treatment that provides surgeons with another option and supports patients’ healing process following operations, GUARDIX-SG™ is a welcome addition to our expanding treatment portfolio,” says Mundipharma CEO, Raman Singh.
“As an organisation, we’re always evaluating innovative treatments that possess significant potential to improve outcomes for patients. GUARDIX-SG™ meets this criterion, and will be of benefits to surgeons and patients across Southeast Asia, so we’re delighted to have signed this agreement with Genewel.”
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.